BeiGene, Ltd.

BeiGene, Ltd.verified

BGNE

Price:

$184.71

Market Cap:

$33.67B

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and ...[Read more]

Industry

Biotechnology

IPO Date

2016-02-03

Stock Exchange

NASDAQ

Ticker

BGNE

The Enterprise Value as of December 2025 (TTM) for BeiGene, Ltd. (BGNE) is 30.65B

According to BeiGene, Ltd.’s latest financial reports and current stock price. The company's current Enterprise Value is 30.65B. This represents a change of 17.06% compared to the average of 26.19B of the last 4 quarters.

BeiGene, Ltd. (BGNE) Historical Enterprise Value (quarterly & annually)

How has BGNE Enterprise Value performed in the past?

The mean historical Enterprise Value of BeiGene, Ltd. over the last ten years is 11.85B. The current 30.65B Enterprise Value has changed 25.76% with respect to the historical average. Over the past ten years (40 quarters), BGNE's Enterprise Value was at its highest in in the September 2025 quarter at 34.53B. The Enterprise Value was at its lowest in in the March 2016 quarter at 741.79M.

Quarterly (TTM)
Annual

Average

11.85B

Median

12.92B

Minimum

872.38M

Maximum

21.46B

BeiGene, Ltd. (BGNE) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of BeiGene, Ltd. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 374.26%

Maximum Annual Enterprise Value = 21.46B

Minimum Annual Increase = -39.95%

Minimum Annual Enterprise Value = 872.38M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
202417.90B10.26%
202316.23B-16.36%
202219.41B-9.54%
202121.46B3.42%
202020.75B115.82%
20199.61B32.39%
20187.26B75.52%
20174.14B374.26%
2016872.38M-2.58%
2015895.48M-39.95%

BeiGene, Ltd. (BGNE) Average Enterprise Value

How has BGNE Enterprise Value performed in the past?

The current Enterprise Value of BeiGene, Ltd. (BGNE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

17.85B

5-year avg

19.15B

10-year avg

11.85B

BeiGene, Ltd. (BGNE) Enterprise Value vs. Peers

How is BGNE’s Enterprise Value compared to its peers?

BeiGene, Ltd.’s Enterprise Value is greater than Ginkgo Bioworks Holdings, Inc. (764.00M), greater than Karuna Therapeutics, Inc. (12.43B), greater than Cerevel Therapeutics Holdings, Inc. (7.68B), greater than IVERIC bio, Inc. (5.13B), greater than Blueprint Medicines Corporation (8.36B), greater than Abiomed, Inc. (17.05B), greater than Prometheus Biosciences, Inc. (9.30B), greater than Roivant Sciences Ltd. (14.34B), greater than SpringWorks Therapeutics, Inc. (3.48B), greater than DICE Therapeutics, Inc. (1.82B),

Build a custom stock screener for BeiGene, Ltd. (BGNE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BeiGene, Ltd. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

BeiGene, Ltd. (BGNE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like BeiGene, Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is BeiGene, Ltd.'s Enterprise Value?

What is the highest Enterprise Value for BeiGene, Ltd. (BGNE)?

What is the 3-year average Enterprise Value for BeiGene, Ltd. (BGNE)?

What is the 5-year average Enterprise Value for BeiGene, Ltd. (BGNE)?

How does the current Enterprise Value for BeiGene, Ltd. (BGNE) compare to its historical average?